FHL2 promotes the aggressiveness of lung adenocarcinoma by inhibiting autophagy via activation of the PI3K / AKT / mTOR pathway
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Shuaishuai Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Guangdong Province, China, Science and Technology Program of Guangzhou, China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Background
Increasing evidence indicates that four and a half LIM domains 2 (FHL2) plays a crucial role in the progression of various cancers. However, the biological functions and molecular mechanism of FHL2 in lung adenocarcinoma (LUAD) remain unclear.
Methods
We evaluated the prognostic value of FHL2 in LUAD using public datasets and further confirmed its prognostic value with our clinical data. The biological functions of FHL2 in LUAD were evaluated by in vitro and in vivo experiments. Pathway analysis and rescue experiments were subsequently performed to explore the molecular mechanism by which FHL2 promoted the progression of LUAD.
Results
FHL2 was upregulated in LUAD tissues compared to adjacent normal lung tissues, and FHL2 overexpression was correlated with unfavorable outcomes in patients with LUAD. FHL2 knockdown significantly suppressed the proliferation, migration and invasion of LUAD cells, while FHL2 overexpression had the opposite effect. Mechanistically, FHL2 upregulated the PI3K/AKT/mTOR pathway and subsequently inhibited autophagy in LUAD cells. The effects FHL2 on the proliferation, migration and invasion of LUAD cells are dependent on the inhibition of autophagy, as of induction autophagy attenuated the aggressive phenotype induced by FHL2 overexpression.
Conclusions
FHL2 promotes the progression of LUAD by activating the PI3K/AKT/mTOR pathway and subsequently inhibiting autophagy, which can be exploited as a potential therapeutic target for LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Yanbin Zhou
Förderung
- Natural Science Foundation of Guangdong Province, China
- Science and Technology Program of Guangzhou, China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Wang, S., Liu, B., Su, Y., Wang, N., Dong, P., Xu, X., Huang, L., Li, S., Gu, J., Qiu, Y., Deng, J., Lin, Z., & Zhou, Y. (2024). FHL2 promotes the aggressiveness of lung adenocarcinoma by inhibiting autophagy via activation of the PI3K / AKT / mTOR pathway. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15234
Vancouver
Wang S, Liu B, Su Y, Wang N, Dong P, Xu X, et al. FHL2 promotes the aggressiveness of lung adenocarcinoma by inhibiting autophagy via activation of the PI3K / AKT / mTOR pathway. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15234
BibTeX
@article{Wang2024,
author = {Wang, Shuaishuai and Liu, Baomo and Su, Yan and Wang, Nian and Dong, Peixin and Xu, Xiongye and Huang, Lixia and Li, Shaoli and Gu, Jincui and Qiu, Yanli and Deng, Jiating and Lin, Ziying and Zhou, Yanbin},
title = {FHL2 promotes the aggressiveness of lung adenocarcinoma by inhibiting autophagy via activation of the PI3K / AKT / mTOR pathway},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15234}
}
EUVIMED